| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 3.90 mm | 3.90 mm | 3.90 mm | 3.90 mm | 3.90 mm | 3.90 mm |
| Cash burn (monthly) | 247.67 k | 534.33 k | 485.67 k | 2.00 mm | 585.67 k | 1.39 mm |
| Cash used (since last report) | 1.13 mm | 2.44 mm | 2.22 mm | 9.13 mm | 2.68 mm | 6.35 mm |
| Cash remaining | 2.77 mm | 1.46 mm | 1.68 mm | -5.23 mm | 1.22 mm | -2.45 mm |
| Runway (months of cash) | 11.2 | 2.7 | 3.5 | -2.6 | 2.1 | -1.8 |
| 13F holders | Current |
|---|---|
| Total holders | 17 |
| Opened positions | 3 |
| Closed positions | 16 |
| Increased positions | 4 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 151.95 mm |
| Total shares | 3.16 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| FBIO Fortress Biotech | 2.52 mm | $1.18 mm |
| Geode Capital Management | 245.49 k | $57.76 mm |
| Koss-Olinger Consulting | 98.37 k | $23.00 mm |
| BlackRock | 83.34 k | $19.61 mm |
| Vanguard | 75.39 k | $17.72 mm |
| HB Wealth Management | 40.00 k | $9.41 mm |
| PFG Investments | 22.12 k | $5.21 mm |
| NTRS Northern Trust | 16.91 k | $3.98 mm |
| STT State Street | 16.02 k | $3.77 mm |
| Jamison Private Wealth Management | 15.00 k | $3.53 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 27 Jun 24 | Fortress Biotech | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 575,191 | 0.00 | 2,502,991 |
| 31 May 24 | Litchman Manuel MD | Common Stock | Payment of exercise | Dispose F | No | No | 0.35 | 1,396 | 488.60 | 83,024 |
